Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | FASN | P49327 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5492701 | 0.91 | ALDH1A1 (0.56) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28891615 | 0.88 | MEN1 (0.54) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2566187 | 0.85 | MCHR1 (0.53) | CHRM2CHRM3OPRM1 | |
| SCHEMBL2712659 | 0.82 | MEN1 (0.62) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20477164 | 0.82 | S1PR5 (0.53) | — | |
| SCHEMBL12614550 | 0.82 | GPR119 (0.41) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11407980 | 0.81 | MEN1 (0.65) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28017518 | 0.81 | CHRM2 (0.50) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1526062 | 0.80 | FFAR4 (0.49) | ALDH1A1 | |
| SCHEMBL12614459 | 0.79 | CHRM3 (0.52) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008316-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2021-05-18 | — | — | US | disclosed |
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2018-03-08 | — | — | US | disclosed |
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
| EP-2361242-A1 | OXIDASE INHIBITORS AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2011-08-31 | — | — | EP | disclosed |
| WO-2010043721-A1 | OXIDASE INHIBITORS AND THEIR USE | ORYZON GENOMICS, S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NPC1 100/4885RAB9A 699/4885MEN1 1532/4885 |
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NPC1 100/4885RAB9A 699/4885MEN1 1532/4885 |
| US-11008316-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GAA | NPC1 79/4885RAB9A 641/4885MEN1 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.